Register now
Nordic Life Science Days 2016
14-15 september 2016
Waterfront, Stockholm, Sweden
© 2020 Bionordic. All Rights Reserved
Nordic Life Science Days 2016
14-15 september 2016
Waterfront, Stockholm, Sweden
© 2020 Bionordic. All Rights Reserved
This NLSDays 2020 Pre-Event will be a private, by-invitation only event. Participants will arrive in Malmö one day prior to NLSDays to experience a full-day program alongside relevant industry and financial parties. The day will include interactive workshops, educational sessions, discussions, and pitches, etc.
Moderator(s): Ms. Helena Strigård - Director General, SwedenBIO
Speaker(s):
Mr. Olivier Duchamp - Managing Director, NLSDays - NLS Invest
Mr. Emmanuel Ligner - CEO & President at Cityva (former GE Healthcare Life Sciences)
Mr. Erik Gatenholm - CEO and Co-Founder, Cellink
Dr. Rafiq Hasan - CEO, ExACT Therapeutics
In the Nordics, we are sitting on a vast number of viable data sources – and data, as we know, is key to our industry’s ability to thrive. As such, we must cooperate to better align, integrate, and use our data sources in a protected and patient-centric way that also supports industry participation. In this session, we look at examples of successful collaboration models, at how data helps to drive the value of an asset, at the importance of industry, and at the reciprocal requirement to address and articulate societal value.
Speaker(s):
Ms. Rajji Mehdwan - General Manager, Roche Norway
Dr. Lars Lindsköld - Portfolio manager, Sweper / Swelife
Dr. Nikolai Brun - Chair HMA-EMA Taskforce on Big Data
Ms. Louise Rosenlund Nielsen - Head of International Development & Partnerships, CopCap
The human microbiome is considered to be a counterpart to the human genome, with the number of genes in our microbiome outnumbering the genes in our genome by 100 to 1. We also know that understanding and thus balancing our microbiome is vital to human health and that our microbes are impacted on a community, rather than individual, level.
In this session, “Microbiome: the New Genetics?” hosted by the Greater Copenhagen Microbiome Signature Project, we will hear from some of the world’s leaders on the current developments within microbiome research, such as host-microbe interactions and their implications on disease progression and treatment, where opportunities and challenges exist in translating proof-of-concept studies in animal models to clinical trials, and how research can transition from academia to industry to result in improved therapies and better therapeutic outcomes for patients.
The discussions will further shed light on how the Nordics can play a key role in moving the field forward.
Moderator(s): Dr. Eric De La Fortelle - Venture Partner, Seventure Partners
Speaker(s):
Dr. Mirjam Mol-Arts - SVP Global Development, Ferring Pharmaceuticals
Dr. Henrik Bjørn Nielsen - Chief Scientific Officer, Clinical Microbiomics
Dr. Gianfranco Grompone - Chief Scientific Officer, BioGaia
Ms. Sarah Lidé - Senior Strategy & Project Manager, Medicon Valley Alliance
Our world has seen an emergence and re-emergence of infectious and contagious diseases, albeit rather controlled and isolated outbreaks – until now. COVID-19 has propelled us into a new era, one in which the impacts of globalization, travel, and climate change on our collective health and safety are evident. Many new questions are now upon us:
In this session, we will tackle as much as we can, given what we know & are continuing to learn.
While our life science industry is full of exciting innovations, many companies are wary of shouting about their accomplishments, both culturally and in such a strictly regulated environment. At the same time, the world won’t notice your company unless you provide compelling information about who you are and how you are changing the game.
It’s vital that potential stakeholders understand that you are developing the best solution to the problems they face. Therefore, you must be able to present them with the bold vision behind what your innovation means to the market, alongside a relevant brand story.
Join us in this interactive fireside chat to learn about the power of branding in differentiating you from your competitors and in influencing customer perceptions through storytelling.
Approaching the financial community can be a daunting task, one made greater if we don’t know our particular audiencewell enough. In this session, we focus on hunting intelligently. We highlight different ways of thinking between varying types of investors and then deep-dive into the venture world to better understand what venture capital really is, what are its pros and cons, how to find the right match, and what to know about a rejection. Expect a dialogue, so come prepared with your questions!
Moderator(s): Dr. Sonia Benhamida - Senior Vice President Healthcare, DNB
Speaker(s):
Dr. Ingrid Teigland Akay - Managing Partner, Hadean Ventures
Dr. Christina Trojel-Hansen - CEO and Co-Founder - Oscine Therapeutics, in Residence - Arch Venture Partners
Ms. Isabelle de Cremoux - CEO & Managing Partner, Seventure Partners
Tackling global health challenges requires that we move from ‘reactive’ to ‘proactive’ care, and that we personalize our approach. The practice of evidence-based medicine and the continued identification of new biomarkers are vital steps in improving disease diagnosis, improving the safety and efficacy of existing medicines, and in developing new medicines and targeted therapies. In this session, we discuss the needs and challenges from both industry and financial viewpoints.
Speaker(s):
Ms. Karin Conde-Knape - CVP Global Diabetes, Cardio-Renal and Global Drug Discovery, Novo Nordisk
Ms. Carolina Haefliger - VP, Head Centre for Genomics Research, AstraZeneca
Dr. Patrick Sobocki - Investment Manager, Industrifonden
In the world of exponential data and digital disruption, there are more players involved in R&D than ever before. Traditional business models across the drug discovery and development value chain are, therefore, transitioning at an increasingly rapid pace. In this session, we take a look at the new playground: who is involved, how are they working together, and what does this mean for the future of clinical trials from academic, pharma, technology, and regulatory perspectives.
Speaker(s):
Mr. Martin Olovsson - CEO and Co-Founder, Ondosis
Dr. Magnus Björsne - CEO, Astrazeneca BioVentureHub
Dr. Jessica Shull - European Lead, Digital Therapeutics Alliance
Dr. Sam Oddsson - Chief Medical Officer & Co-Founder, SidekickHealth
Dr. Elisabeth Liljensten - CEO, Devicia
